Close

Selventa receives new patent for discovery of biomarker profiles

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Why Early Intervention Is Key To Managing Chronic Health Concerns

Proactive health management is essential for maintaining a good...

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Selventa, a biomarker discovery company, has received US patent entitled Computer-aided Discovery of Biomarker Profiles in Complex Biological Systems.

The patent is related to methods and techniques that facilitate discovery of biomarkers and aid in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.

The patent describes a method of biomarker discovery using a model representative of one or more causative biophysical or biochemical relationships underlying a biological state in a biological system.

A candidate set of biological data is compared against the model to discern a candidate biomarker for the biological state.

A sample received from a patient will be assayed for the presence of the candidate biomarkers to discern a biological state of the patient.

Selventa president and CEO David Graaf said that using the technique, biomarkers may be developed to predict efficacy or toxic effects of a drug.

 

Latest stories